BMRN vs TGTX: stock comparison and AI forecast
Biomarin Pharmaceutical Inc (BMRN) and Tg Therapeutics, Inc. (TGTX) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
BMRN Biomarin Pharmaceutical Inc
- Price
- $55.66 +4.5% · 6M
- Market Cap
- $10.77B
- P/E Ratio
- 556.6x
- Size
- large-cap
- AI Forecast
TGTX Tg Therapeutics, Inc.
- Price
- $58.08 +71.9% · 6M
- Market Cap
- $9.22B
- P/E Ratio
- 21.9x
- Size
- mid-cap
- AI Forecast
- NO CURRENT FORECAST
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- BMRN is 1.2 times larger than TGTX by market capitalization ($10.77B against $9.22B).
- TGTX trades at 21.9 times trailing earnings, BMRN at 556.6 times.
- Over the last six months TGTX returned +71.9% and BMRN +4.5%.
- TGTX carries 1.71 times debt per unit of equity, against 0.85 times for BMRN.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | BMRN | TGTX |
|---|---|---|
| Market Cap | $10.77B | $9.22B |
| P/E Ratio | 556.61x | 21.92x |
| P/B Ratio | 1.72x | 15.26x |
| EPS | $0.10 | $2.65 |
| Book Value/Share | $32.32 | $3.81 |
| Revenue/Share | $18.88 | $5.04 |
| FCF/Share | $2.88 | $0.11 |
Profitability & Margins
| Metric | BMRN | TGTX |
|---|---|---|
| ROE | – | 73.1% |
| ROA | – | 26.9% |
| ROIC | 1.1% | 9.9% |
| Gross Margin | 76.0% | 82.4% |
| Operating Margin | 3.1% | 17.1% |
| Net Margin | – | 55.2% |
| EBT Margin | 1.2% | 12.7% |
| Tax Rate | 143.8% | -334.5% |
Financial Health
| Metric | BMRN | TGTX |
|---|---|---|
| Current Ratio | 2.44x | 4.27x |
| Quick Ratio | 1.32x | 3.72x |
| D/E Ratio | 0.85x | 1.71x |
| Financial Leverage | 1.85x | 2.71x |
| Interest Coverage | – | 1.2x |
| Working Capital | $2.32B | $877M |
Cash Flow
| Metric | BMRN | TGTX |
|---|---|---|
| Operating Cash Flow | $677M | $18M |
| Free Cash Flow | $558M | $17M |
| Capital Spending | -$119M | -$490K |
| OCF Growth YoY | -26.0% | – |
| FCF Growth YoY | -33.0% | – |
| FCF/Sales | 15.3% | 2.2% |
| CapEx/Sales | 3.2% | 0.1% |
Operational Efficiency
| Metric | BMRN | TGTX |
|---|---|---|
| Asset Turnover | 0.32x | 0.49x |
| Receivables Turnover | 3.4x | 2.0x |
| Inventory Turnover | 0.5x | 0.9x |
| Fixed Assets Turnover | 3.7x | – |
| Days Sales Outstanding | 107 days | 183 days |
| Days Inventory | 746 days | 383 days |
| Payables Period | 54 days | – |
| Cash Conversion Cycle | 799 days | – |
Income Statement
| Metric | BMRN | TGTX |
|---|---|---|
| Total Revenue | $3.66B | $800M |
| Operating Income | $114M | $136M |
| Net Income | – | $441M |
| R&D Expense | $759M | $226M |
| SG&A Expense | $1.43B | $296M |
| Cost of Goods Sold | $879M | $141M |
Dividend & Shareholder Information
| Metric | BMRN | TGTX |
|---|---|---|
| Shares Outstanding | 194M | 159M |
| Net Income Growth | – | 630.2% |
| EPS Growth | -95.4% | 846.4% |
BMRN vs TGTX: stock comparison and AI forecast
Which is bigger, BMRN or TGTX?
BMRN is 1.2 times larger than TGTX by market capitalization ($10.77B against $9.22B).
Which is cheaper on earnings, BMRN or TGTX?
TGTX trades at 21.9 times trailing earnings, BMRN at 556.6 times.
Which stock performed better over the last six months, BMRN or TGTX?
Over the last six months TGTX returned +71.9% and BMRN +4.5%.
Which one does Intratio's AI model rank higher, BMRN or TGTX?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.